Management of Large Non‑Mass Enhancement (≥6 cm) on Breast MRI

Diagnostic Workup

MRI‑guided core needle biopsy is the definitive next step for a 6 cm non‑mass enhancement that is only visible on MRI – it provides the required histologic diagnosis. 1
Second‑look targeted ultrasound should be performed to identify a possible sonographic correlate that would allow an ultrasound‑guided biopsy, which is more accessible, less costly, and technically easier. 4
If a sonographic correlate is found, ultrasound‑guided biopsy is preferred over MRI‑guided biopsy. 4
Diagnostic mammography (including tomosynthesis when available) is recommended to evaluate for associated calcifications or architectural distortion that could guide a stereotactic biopsy. 4

Non‑mass enhancement accounts for 58 % of DCIS cases on MRI and carries a malignancy rate of 10–25 %, varying with specific morphologic features. 1
MRI tends to overestimate DCIS size by a mean of 1.97–3.2 cm, meaning the true disease burden may still be substantial even after accounting for this overestimation. 1
Large non‑mass enhancement (≥6 cm) markedly increases the likelihood of multifocal/multicentric disease and the potential upgrade to invasive cancer. 1

Place a marker clip at the biopsy site to facilitate surgical localization if malignancy is confirmed. 4

Benign result concordant with imaging – short‑interval follow‑up imaging at 6 months may be considered, although the large size often still warrants surgical excision. 4
Atypical histology (ADH, ALH, LCIS) – surgical excision is recommended because of a high upgrade risk. 4
Benign result discordant with imaging – surgical excision is mandatory. 4
Malignant result (DCIS or invasive cancer) – proceed to surgical planning according to NCCN breast cancer guidelines. 4

Observation without tissue diagnosis is inappropriate for a 6 cm lesion, regardless of enhancement kinetics or pattern. 1
Even “probably benign” appearing non‑mass enhancement of this extent requires histologic confirmation because of the potential for extensive DCIS. 1
DCIS‑related non‑mass enhancement often shows medium or persistent kinetic curves, which can falsely reassure clinicians. 3
MRI sensitivity for DCIS is 85–92 %, indicating that 8–15 % of DCIS may not enhance and could be missed. 3

MRI detects 88 % of DCIS lesions and predicts upgrade to invasive disease in 82 % of cases in one study. 1
A 6 cm extent generally suggests mastectomy rather than breast‑conserving therapy, though final decisions depend on histology and patient preference. 1
MRI adds an additional cancer detection rate of 6.2 % for ipsilateral disease and can identify contralateral malignancies. 1
When present, MRI predicts multicentric disease in 90 % of cases, underscoring the need for comprehensive surgical planning. 1
The large 6 cm area raises substantial concern for multifocal or multicentric disease, influencing the choice of surgical approach. 1